Sign in Subscribe
Class action lawsuits

Cytokinetics, Incorporated Shareholders Encouraged to Contact Gross Law Firm for Possible Class Action Appointment

Strategic Insights

— 2 min read

Pursuant to the notice from The Gross Law Firm, shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK) who purchased shares during the period from December 27, 2023 to May 6, 2025, are urged to contact the firm regarding possible lead plaintiff appointment in a class action lawsuit. The deadline to seek appointment as a lead plaintiff is November 17, 2025.

According to the complaint, defendants made false and misleading statements regarding the timeline for the New Drug Application ("NDA") submission and approval process for aficamten. Specifically, defendants represented that the Company expected approval from the U.S. Food and Drug Administration ("FDA") for its NDA for aficamten in the second half of 2025, based on a September 26, 2025 PDUFA date. However, on May 6, 2025, during an earnings call, it was revealed that the Company had multiple pre-NDA meetings with the FDA discussing safety monitoring and risk mitigation but chose to submit the NDA without a REMS, relying on labeling and voluntary education materials.

As a result of defendants' false and misleading statements, class members purchased Cytokinetics' common stock at artificially inflated prices and suffered significant losses when the truth was revealed.

Key Takeaways:

  • The class period listed for shareholders affected by the Cytokinetics, Incorporated class action lawsuit is from December 27, 2023 to May 6, 2025.
  • The deadline to seek appointment as a lead plaintiff in this case is November 17, 2025.
  • The Gross Law Firm, a nationally recognized class action law firm, seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by the company lead to artificial inflation of the company's stock.
  • Defendant Cytokinetics, Incorporated allegedly made false and misleading statements regarding the timeline for the New Drug Application ("NDA") submission and approval process for aficamten.
  • On May 6, 2025, during an earnings call, it was revealed that the Company had multiple pre-NDA meetings with the FDA discussing safety monitoring and risk mitigation but chose to submit the NDA without a REMS.
  • The Company's reliance on labeling and voluntary education materials instead of submitting a REMS led to artificially inflated prices for Cytokinetics' common stock.
  • As a result, class members purchased Cytokinetics' common stock at artificially inflated prices and suffered significant losses when the truth was revealed.

Statistics:

  • The class period for the Cytokinetics, Incorporated class action lawsuit is from December 27, 2023 to May 6, 2025.
  • The deadline to seek appointment as a lead plaintiff in this case is November 17, 2025.
  • The period from December 27, 2023 to May 6, 2025, is 17 months.

Sources:

  • GlobeNewswire, "Notice is hereby given to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK)," October 30, 2025
  • The Gross Law Firm, "Cytokinetics, Incorporated (NASDAQ: CYTK) Class Action Lawsuit & Stockholder Information," 2025

Read more